You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Classic 5-HT1A partial agonist with relatively high affinity (Ki = 9.3 - 29.5 nM). A clinically effective anxiolytic.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 421.97. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.37 mL||11.85 mL||23.7 mL|
|5 mM||0.47 mL||2.37 mL||4.74 mL|
|10 mM||0.24 mL||1.18 mL||2.37 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
References are publications that support the biological activity of the product.
Cao and Rodgers (1997) Comparative behavioural profiles of busp. and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 36 1089 PMID: 9294974
Goa and Ward (1986) Buspirone - a preliminary review on its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32 114 PMID: 2874976
Gobert et al (1999) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of DA, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of α2-adrenoceptors underlie i Neuroscience 93 1251 PMID: 10501449
Merck Index 12 1528
If you know of a relevant reference for Buspirone hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Buspirone hydrochloride, Buspirone hydrochloride supplier, 5-HT1A, partial, agonists, Serotonin, Receptors, 0962, Tocris Bioscience
3 Citations for Buspirone hydrochloride
Citations are publications that use Tocris products. Selected citations for Buspirone hydrochloride include:
Gutierrez et al (2019) Endothelin neurotransmitter signalling controls zebrafish social behaviour. Sci Rep 9 3040 PMID: 30816294
Norton and Gutiérrez (2019) The three-spined stickleback as a model for behavioural neuroscience. PLoS One 14 e0213320 PMID: 30913214
Garavaglia et al (2010) Adaptation of NS cells growth and differentiation to high-throughput screening-compatible plates. BMC Neurosci 11 7 PMID: 20085655
Do you know of a great paper that uses Buspirone hydrochloride from Tocris? Please let us know.
Reviews for Buspirone hydrochloride
There are currently no reviews for this product. Be the first to review Buspirone hydrochloride and earn rewards!
Have you used Buspirone hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.